Thanks Hottod. I guess not understanding the science maybe as...

Thanks Hottod. I guess not understanding the science maybe as well as others doesn't help, but i guess i still go by comments from some corners a long time ago that the mouse model hides a lot of issues with multi cell penetration, and the fact that effects can be seen in mouse model that may not translate so well to primate or human type models.
The effect of the cpp being absorbed by many more cells of various types in humans leads to more off target effects or requirement for much larger doses and consideration of the effect when absorbed or penetrating unintended target cells.

It seemed to me that this had been our stumbling block for some time. We were told that endosomal escape was the holy grail and we supposedly achieved that at will years ago, yet no deals of any description as yet. This told me the issue was cpps were not cell specific and whatever we did didnt seem to work as well outside mouse model, and it seemed the market new this which was why we drifted so low for a while. The shake up of the board then the decision to target the eye, to limit cell exposure i suspect, seemed such an elegant solution to these issues and obviously the market appears to agree at least to some degree. I assume the company will never say we are targetting the eye due to problems with off target cell penetration in the body, but it seems that way. The results you refer to are mouse model DMD and spinal muscular atrophy so i assume same argument, easier to achieve penetration of correct cells without toxicity at lower dose, and those in the know assume that doesnt extrapolate out to same effect in humans due to sink effect of off target absorption. I assume the cell specific question is why we didnt get interest like we have now with something that really looks like it could work in human model even before we actually try. i am no scientist so just calling it how i see it.

i guess i will need to try and clarify with the company somehow if we do have an issue or are making progress with possible human cell specificity from an iv type application. If we could achieve that somehow then the billions might truly be in sight. At the moment the only thing ive seen like that is immuno therapy, where the immune system is trained to attack certain cell types for want of a better description. I thought we were onto something with imyc and tumors, especially when sp jumped on mouse model omomyc results, it seemed to me in hindsight this was shelved because the tumor was probably the last thing to absorb the cpp imyc conjugate in human version?

Either way good to see the progress to a feasible target in the eye that even i can see makes sense, bad that it has been already wrapped up and put in a box and partially separated from the parent company. Obviously pyc have some ownership but right now i am having to trust the board will do the right thing so i can get a return on that entity.